

# BRIEF REPORT Outcomes following intolerance to calcineurin-inhibitor based graft-versus-host disease prophylaxis in children after allogeneic hematopoietic cell transplantation

Ashok Srinivasan<sup>1</sup>, Diana Wu<sup>1</sup>, Ying Li<sup>1</sup>, YU BI<sup>1</sup>, Trevor Lannom M<sup>1</sup>, Deborah Ward<sup>1</sup>, Amr Qudeimat<sup>1</sup>, Renee Madden<sup>1</sup>, Akshay Sharma<sup>1</sup>, Rebecca Epperly<sup>1</sup>, Ewelina Mamcarz<sup>1</sup>, Aimee Talleur<sup>1</sup>, Swati Naik<sup>1</sup>, Subodh Selukar<sup>1</sup>, and Brandon Triplett<sup>1</sup>

<sup>1</sup>St Jude Children's Research Hospital Department of Oncology

April 12, 2023

## Abstract

Calcineurin inhibitors (CNI), cyclosporine and tacrolimus, are commonly used for pharmacotherapeutic prophylaxis of Graft-vs.-Host disease after hematopoietic cell transplantation (HCT). Unfortunately, their use is associated with significant toxicities. While intolerance to CNI is well defined, there is very little data on how they impact outcomes after HCT in children. Our retrospective study in a cohort of 82 children, shows a high intolerance rate of 39% in this population associated with lower event free survival and a higher transplant-related mortality.

## Hosted file

Manuscript\_Srinivasan.docx available at <https://authorea.com/users/605604/articles/635039-brief-report-outcomes-following-intolerance-to-calcineurin-inhibitor-based-graft-versus-host-disease-prophylaxis-in-children-after-allogeneic-hematopoietic-cell-transplantation>

## Hosted file

Figure1.docx available at <https://authorea.com/users/605604/articles/635039-brief-report-outcomes-following-intolerance-to-calcineurin-inhibitor-based-graft-versus-host-disease-prophylaxis-in-children-after-allogeneic-hematopoietic-cell-transplantation>